Does Zepbound Work Better Than Wegovy?

Last reviewed: June 28, 2026

Last updated: June 28, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Both Zepbound and Wegovy have become household names in weight loss treatment, yet they operate through distinct biological pathways. Zepbound contains tirzepatide, which activates two hormone receptors (GLP-1 and GIP), while Wegovy contains semaglutide, which activates the GLP-1 receptor alone. Understanding these differences helps you determine which medication might align better with your unique metabolism and health goals.

How Tirzepatide in Zepbound Differs From Semaglutide in Wegovy

Tirzepatide is a dual-action molecule that activates both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. This dual mechanism allows tirzepatide to work on appetite control through two separate pathways simultaneously. Semaglutide, by contrast, activates only the GLP-1 receptor, making it a single-pathway intervention. Because tirzepatide engages more receptors across more tissues, some patients experience faster or more pronounced weight reduction.

The GIP receptor activation in tirzepatide also influences energy expenditure and nutrient absorption differently than GLP-1 alone. Clinical data shows that dual-receptor activation can produce weight losses ranging from 22% to 28% of body weight over 68 weeks in study populations. Semaglutide typically produces weight losses between 15% and 18% over similar timeframes. However, individual outcomes vary dramatically based on genetic factors, baseline metabolism, lifestyle adherence, and hormone sensitivity.

Clinical Trial Outcomes: Zepbound Tirzepatide vs Wegovy Semaglutide

The SURMOUNT-3 trial demonstrated that tirzepatide achieved mean weight reductions of 22.2% (approximately 52 pounds) in participants receiving the highest approved dose over 68 weeks. The comparable semaglutide trial (STEP 4) showed mean reductions of 17.4% (approximately 40 pounds) at the highest dose over 68 weeks. These aggregate numbers mask significant individual variability—some patients on semaglutide achieve 25%+ weight loss, while others on tirzepatide may see 12% reductions depending on their genetic predisposition and metabolic profile.

Beyond weight loss alone, tirzepatide studies reported greater improvements in waist circumference and visceral fat mass compared to semaglutide cohorts. Both medications lowered HbA1c (blood sugar control), but tirzepatide showed numerically larger improvements in insulin sensitivity. Gastrointestinal side effects were comparable between both compounds, though the pattern and severity differed individually. Trial outcomes cannot predict personal response, which is why genetic insight into peptide sensitivity becomes valuable for treatment personalization.

Why Individual Response to Zepbound vs Wegovy Varies So Widely

Genetic variation in GLP-1 receptor (GLP1R) and GIP receptor (GIPR) expression determines how sensitive your cells are to these medications. Someone carrying the GLP1R rs6923761 T allele may experience heightened appetite suppression on semaglutide alone, while a carrier of the GIPR rs1800437 variant might see superior results with tirzepatide's dual activation. Additionally, FTO gene variants (rs9939609) influence baseline metabolic rate and fat storage tendency, affecting how much weight loss either compound can achieve. MC4R variants (rs17782313) affect hunger signaling and reward pathways, influencing medication responsiveness.

Environmental factors—sleep quality, stress hormones, physical activity, macronutrient composition—also modulate medication efficacy in ways that genetic testing cannot fully capture. A person with optimal sleep, structured exercise, and stable cortisol may lose 30% body weight on either medication, while sleep-deprived individuals with chronic stress may plateau at 8–10% loss despite identical dosing. This explains why two patients on identical doses can experience vastly different outcomes. PlexusDx's Precision Peptide Genetic Test maps 14 metabolic pathways across 49 peptides and 150+ genetic insights to illuminate your individual peptide-sensitivity profile.

Choosing Between Tirzepatide and Semaglutide at PlexusDx

PlexusDx offers both compounded tirzepatide injection (starting at $249/month) and compounded semaglutide injection (starting at $149/month) from licensed 503A compounding pharmacies, providing options for different metabolic profiles and budgets. Your dose may need to go up as tolerance develops or weight loss plateaus, but your price won't change—PlexusDx pricing is flat per compound regardless of dose level. Many patients begin with semaglutide to assess GLP-1 pathway sensitivity before considering tirzepatide's dual activation, while others start with tirzepatide for faster initial results.

The Precision Peptide Genetic Test ($99 add-on after your first month of treatment) provides a personalized roadmap of your 14 metabolic pathways, helping you and your PlexusDx clinician make informed decisions about which medication aligns with your genetic predisposition. Some patients with strong GIPR sensitivity benefit from tirzepatide's GIP component, while others with robust GLP-1R activity see excellent outcomes on semaglutide alone. This data-driven approach removes guesswork and optimizes your likelihood of sustained weight loss. PlexusDx serves all 50 states with no insurance required and accepts HSA/FSA funds.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is Zepbound (tirzepatide) more effective than Wegovy (semaglutide) for everyone?

No. While tirzepatide shows higher average weight loss in trials, individual response depends on your genetic GLP-1 and GIP receptor sensitivity, baseline metabolism, and lifestyle factors. Some patients achieve equal or superior results on semaglutide due to individual variations in peptide-pathway activation. PlexusDx's Precision Peptide Genetic Test helps predict your likely response pattern.

What does the GIP receptor do that makes tirzepatide different?

The GIP receptor regulates nutrient-dependent insulin secretion, energy expenditure, and fat oxidation independently from GLP-1. Activating both GLP-1 and GIP receptors simultaneously increases appetite suppression, slows gastric emptying more effectively, and improves insulin sensitivity beyond GLP-1 activation alone. This dual action explains tirzepatide's larger average weight-loss outcomes in clinical trials.

What does tirzepatide cost at PlexusDx compared to semaglutide?

Compounded tirzepatide injection starts at $249/month, while compounded semaglutide injection starts at $149/month. Both are available from licensed 503A compounding pharmacies, require no insurance, and accept HSA/FSA funds. Your dose may increase over time, but your monthly price remains flat at PlexusDx.

Are the side effects different between Zepbound and Wegovy?

Both medications cause similar gastrointestinal side effects (nausea, vomiting, constipation, diarrhea), though individual severity and pattern vary. Tirzepatide's dual action may cause slightly different symptom timing due to the additional GIP pathway. Side effects typically diminish after 4–8 weeks as your body adapts to the medication.

Can the Precision Peptide Genetic Test predict whether I'll do better on tirzepatide or semaglutide?

Yes. The test analyzes key variants in GLP1R, GIPR, FTO, and MC4R genes across 14 metabolic pathways, revealing your peptide-sensitivity profile. Carriers of certain GIPR variants often show enhanced tirzepatide response, while robust GLP1R expression may yield excellent semaglutide outcomes. This $99 add-on test (available after your first treatment month) guides your medication choice and optimizes efficacy.

Related Reading

• Wegovy Vs Zepbound 2
• Zepbound Vs Wegovy 2
• Wegovy Vs Zepbound Weight Loss
• Zepbound Vs Wegovy Cost

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.